Pfizer and biontech receive positive chmp opinion for comirnaty® in children 6 months to less than 5 years in the european union

New york and mainz, germany, october 19, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has recommended marketing authorization (ma) for a 3-Μg dose of comirnaty® (covid-19 vaccine, mrna), which is based on the wild-type spike protein of sars-cov-2, as a three-dose series for children ages 6 months to less than 5 years (also referred to as 6 months through 4 years of age). the european commission will review the chmp recommendation and is expected to make a final decision soon.
BNTX Ratings Summary
BNTX Quant Ranking